Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7616789 in Advanced SCLC and NEC
NCT05619744Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2023
- Primary completion
- Mar 2025
- Modality
- Bispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of RG6538 in small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) (3 arms), sponsored by Roche. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events at 26 months, Number of Participants with Dose Limiting Toxicities at 21 days and 5 more. Started Jan 2023; status: completed.
02
Drugs
RG6538
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT05619744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05619744.